NEW YORK – A research team led by investigators at the Dana-Farber Cancer Institute and the Broad Institute has uncovered somatic mutations linked to immunotherapy resistance in metastatic melanoma patients who experienced disease recurrence and acquired drug resistance after an initial response to immune checkpoint immunotherapy (ICI).
Health Professionals
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
Source: OncLive, February 2025 Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute, provides insight on the…
Read More Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma
Marlana M. Orloff, MD, associate professor, Jefferson University; physician, Department of Medical Oncology, Sidney Kimmel Cancer Center, discusses optimal treatment strategies for patients with aggressive uveal melanoma.
Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma
Mark Faries, MD, surgical oncologist, Cedars?Sinai, The Angeles Clinic and Research Institute; associate director, Surgical Oncology Experimental Therapeutics, Cedars Sinai Department of Surgery; and head, surgical oncology, Cedars-Sinai Medical Center, discusses how CAR T-cell therapies and transgenic T-cell receptor (TCR) cell therapies compare with current tumor-infiltrating lymphocyte (TIL) approaches in melanoma.